Exploring new territory: considering the future

about

Lupus: improving long-term prognosis.Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals.

P2860

Q37121353-1A92E410-ACC6-45E9-8E20-628C3273AE50 Q42086334-FB55B61E-11C3-45CF-B2D3-7D5A04FD5661

P2860

Exploring new territory: considering the future

Item

http://www.wikidata.org/entity/Q28222277

description

2007 nî lūn-bûn

@nan

2007 թուականին հրատարակուած գիտական յօդուած

@hyw

2007 թվականին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Exploring new territory: considering the future

@ast

Exploring new territory: considering the future

@en

Exploring new territory: considering the future

@nl

type

Item

label

Exploring new territory: considering the future

@ast

Exploring new territory: considering the future

@en

Exploring new territory: considering the future

@nl

prefLabel

Exploring new territory: considering the future

@ast

Exploring new territory: considering the future

@en

Exploring new territory: considering the future

@nl

P1476

Exploring new territory: considering the future

@en

P2093

M Schneider

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104

Women in academic rheumatology.

Block and tackle: CTLA4Ig takes on lupus.

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

The type I interferon system in systemic lupus erythematosus.

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

P304

221-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203306075615

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17432111

http://www.w3.org/2001/XMLSchema#string

Exploring new territory: considering the future

about

P2860

P2860

Exploring new territory: considering the future

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698